Roth Capital Reiterates Buy Rating On NeoGenomics, $6 Price Target


Roth Capital analyst Debjit Chattopadhyay today reiterated a “Buy” rating on shares of NeoGenomics Laboratories, Inc. (NEO), and a $6.00 price target.

“We believe NeoGenomics is one of the best-positioned high-complexity oncology reference labs on the brink of significant revenue acceleration. We envision multiple opportunities for the company to beat current expectations and reiterate our Buy rating and $6.00 price target, which is based on a 3.7 multiple to our 2015 revenue estimate and discounted to PV at 12%”, Chattopadhyay wrote.

NEO Chart

 

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts